Repurposing AZD5438 and Dabrafenib for Cisplatin-Induced Acute Kidney Injury.

Chithra K PushpanDaniel F Kresock Matthew A IngersollRichard D LutzeDarby L KeirnsWilliam J HunterKhalid Bashir Tal Teitz

Published in: Journal of the American Society of Nephrology : JASN (2023)

Cisplatin-induced damage to the inner ear and kidneys share similar cellular beneficial responses to AZD5438 and dabrafenib highlighting the potential therapeutic use of these agents to treat both cisplatin-mediated kidney damage and hearing loss.

Keyphrases

acute kidney injury
hearing loss
oxidative stress
cardiac surgery